Efficacy of Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir with Ribavirin in Liver Transplant Recipients with Recurrent HCV GT1

The CORAL-I trial evaluated the safety and efficacy of the 3D regimen (ombitasvir-paritaprevir-ritonavir + dasabuvir) combined with ribavirin for 24 weeks in liver transplant recipients with recurrent HCV genotype 1. The study included treatment-naive individuals after transplantation, with specific

0 views • 8 slides